Bukwang Pharmaceutical Co., Ltd.
003000.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$400.09B
Close$
$6009.80
56.7% upside
Current Fair Value
56.7% upsideUndervalued by 56.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $400.09 Billion |
|---|---|
| Enterprise Value | $376.66 Billion |
| Dividend Yield | $125.00 (3.08%) |
| Earnings per Share | $152 |
| Beta | 0.12 |
| Outstanding Shares | 97,679,000 |
Return
| Return on Equity | 2.67% |
|---|---|
| Return on Assets | 1.91% |
| Return on Invested Capital | 3.30% |
Valuation & Multiples
| P/E Ratio | 67.18 |
|---|---|
| PEG | -85.91 |
| Price to Sales | 1.74 |
| Price to Book Ratio | 1.12 |
| Enterprise Value to Revenue | 1.75 |
| Enterprise Value to EBIT | 32.34 |
| Enterprise Value to Net Income | 42 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 0.24 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bukwang Pharmaceutical Co., Ltd.
650 employees
CEO: Jae-Young Lee Bukwang Pharmaceutical Co., Ltd., a South Korean-based enterprise, conducts pharmaceutical operations both domestically and across international markets. The company manufactures a diverse array of pharmaceutical formats, encompassing or...